Ingredient Repository · Ingredient

🌿
Ingredient

Bifidobacterium infantis

A specialized probiotic strain that metabolizes complex glycans, calms gut inflammation, and supports immune balance.

What it is

Bifidobacterium infantis (Bifidobacterium longum subsp. infantis) is a specialized probiotic strain naturally predominant in infant digestive tracts and present throughout adulthood. Manufactured via controlled anaerobic fermentation and freeze-drying, B. infantis possesses a unique genomic capacity to break down complex oligosaccharides. In Velobiotics formulations, patented MEP microencapsulation shields B. infantis from acidic gastric juice, delivering intact bacteria to the intestines for maximal colonization and immune modulation.

Also known as: B. infantis, Bifidobacterium longum subsp. infantis

What it does

  • Efficiently digests complex prebiotic glycans and oligosaccharides.
  • Promotes anti-inflammatory cytokine signaling in gut mucosa.
  • Supports abdominal comfort and eases functional bowel distress.
  • Helps maintain tight epithelial junction integrity.

Amplified by probiotics

Bifidobacterium infantis exhibits powerful synergistic interactions when combined with other Bifidobacteria and Lactobacilli. Equipped with specialized glycan transporters, B. infantis ferments oligosaccharides to produce abundant short-chain fatty acids (SCFAs), notably acetate and lactate. This enzymatic activity lowers luminal pH, which suppresses harmful microflora and promotes the growth of beneficial companion strains like Lactobacillus plantarum. The increased SCFA concentration nourishes intestinal epithelial cells, upregulating tight junction proteins such as occludin and zonula occludens-1. Protected by Velobiotics MEP microencapsulation during gastric passage, viable B. infantis organisms successfully colonise the intestinal mucosa, reducing inflammatory cascade signaling and improving micronutrient uptake.

Typical dose

1–10 billion CFU/day

The evidence

Evidence: strong

Human clinical research confirms that Bifidobacterium infantis reduces symptoms of irritable bowel syndrome, including bloating, gas, and abdominal pain. Randomized controlled trials demonstrate its ability to modulate systemic immune responses and strengthen intestinal barrier parameters. (Chambers LM 2026, Gynecol Oncol) (Cassís-Nosthas ML 2026, J Vis Exp) (Parrino J 2026, Front Nutr)

  1. Chambers LM, et al. PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy. Gynecol Oncol. 2026;211:74-78 PubMed ↗
  2. Cassís-Nosthas ML, et al. Quantification of Changes in Bifidobacteria and Lactobacilli Colony-forming Units During Rifaximin Treatment and Synbiotic Gel in Healthy Volunteers. J Vis Exp. 2026;: PubMed ↗
  3. Parrino J, et al. Impact of Bifidobacterium infantis supplementation on growth, health outcomes, and gut microbiome features in underweight infants from Pakistan. Front Nutr. 2026;13:1783141 PubMed ↗

Safety & who should check first

Bifidobacterium infantis possesses a strong safety record and is well tolerated in infants, adults, and the elderly. Mild transient digestive adjustments may occur initially, and medically vulnerable patients should seek professional advice.